Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Archives of Public Health = Archives Belges De Sante Publique
|
June 27, 2020
The call for a strategic framework to improve cancer literacy in Europe
Kristine Sørensen, Lydia E Makaroff, Laurie Myers, et al.
Contemporary Clinical Trials
|
March 18, 2022
Towards a more patient-centered clinical trial process: A systematic review of interventions incorporating health literacy best practices
Mehnaz Bader, Linda Zheng, Deepika Rao, et al.
The Pediatric Infectious Disease Journal
|
October 25, 2021
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
Alexander Mills, Laurie Myers, Casey Raudenbush, et al.
Plos One
|
April 24, 2008
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk
Pablo Tebas, William Keith Henry, Roy Matining, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 22, 2011
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s
Grace A McComsey, Douglas Kitch, Paul E Sax, et al.
The Journal of Infectious Diseases
|
May 25, 2011
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202
Grace A McComsey, Douglas Kitch, Eric S Daar, et al.
Therapeutic Innovation & Regulatory Science
|
August 3, 2021
An Innovative Health Literacy Approach Designed to Improve Patient Understanding of Medication Labeling
Kara L Jacobson, Juliette Faughnan, Laurie Myers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 11, 2003
A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)
Robert S Wallis, Robert Kalayjian, Jeffrey M Jacobson, et al.
The Journal of Infectious Diseases
|
September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Annals of Internal Medicine
|
February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Archives of Public Health = Archives Belges De Sante Publique
|
June 27, 2020
The call for a strategic framework to improve cancer literacy in Europe
Kristine Sørensen, Lydia E Makaroff, Laurie Myers, et al.
Contemporary Clinical Trials
|
March 18, 2022
Towards a more patient-centered clinical trial process: A systematic review of interventions incorporating health literacy best practices
Mehnaz Bader, Linda Zheng, Deepika Rao, et al.
The Pediatric Infectious Disease Journal
|
October 25, 2021
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
Alexander Mills, Laurie Myers, Casey Raudenbush, et al.
Plos One
|
April 24, 2008
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk
Pablo Tebas, William Keith Henry, Roy Matining, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 22, 2011
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s
Grace A McComsey, Douglas Kitch, Paul E Sax, et al.
The Journal of Infectious Diseases
|
May 25, 2011
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202
Grace A McComsey, Douglas Kitch, Eric S Daar, et al.
Therapeutic Innovation & Regulatory Science
|
August 3, 2021
An Innovative Health Literacy Approach Designed to Improve Patient Understanding of Medication Labeling
Kara L Jacobson, Juliette Faughnan, Laurie Myers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 11, 2003
A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)
Robert S Wallis, Robert Kalayjian, Jeffrey M Jacobson, et al.
The Journal of Infectious Diseases
|
September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Annals of Internal Medicine
|
February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
Page
of 2